目次

Table of Contents

Chapter 1 Research Methodology
1.1 Country-wise market: Base estimates
1.2 Global market: CAGR calculation
1.3 Region based segment share calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Peptide Therapeutics Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.2.1 Increasing prevalence of cancer
3.2.2 Rising incidences of metabolic disorder
3.2.3 Presence of strong product pipeline portfolio
3.2.4 Technological Advancement
3.3 Market restraint analysis
3.3.1 Stringent regulations
3.4 Key Opportunities Prioritized
3.4.1 Key opportunities prioritized
3.5 Peptide Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s

Chapter 4 Peptide Therapeutics Market: Application Estimates & Trend Analysis
4.1 Peptide Therapeutics market: Application movement analysis
4.2 Cancer
4.2.1 Cancer market, 2017 - 2030 (USD Million)
4.3 Metabolic
4.3.1 Metabolic market, 2017 - 2030 (USD Million)
4.4 Cardiovascular Disorder
4.4.1 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
4.5 Respiratory
4.5.1 Respiratory market, 2017 - 2030 (USD Million)
4.6 GIT
4.6.1 GIT market, 2017 - 2030 (USD Million)
4.7 Anti-infection
4.7.1 Anti-infection market, 2017 - 2030 (USD Million)
4.8 Pain
4.8.1 Pain market, 2017 - 2030 (USD Million)
4.9 Dermatology
4.9.1 Dermatology market, 2017 - 2030 (USD Million)
4.10 CNS
4.10.1 CNS market, 2017 - 2030 (USD Million)
4.11 Renal
4.11.1 Renal market, 2017 - 2030 (USD Million)
4.12 Others
4.12.1 Others market, 2017 - 2030 (USD Million)

Chapter 5 Peptide Therapeutics Market: Type Estimates & Trend Analysis
5.1 Peptide Therapeutics market: Type movement analysis
5.2 Generic
5.2.1 Generic Market, 2017 - 2030 (USD Million)
5.3 Innovative
5.3.1 Innovative Market, 2017 - 2030 (USD Million)

Chapter 6 Peptide Therapeutics Market: Type of Manufacturers Estimates & Trend Analysis
6.1 Peptide Therapeutics market: Type of Manufacturers movement analysis
6.2 In-house
6.2.1 In-house market, 2017 - 2030 (USD Million)
6.3 Outsourced
6.3.1 Outsourced market, 2017 - 2030 (USD Million)

Chapter 7 Peptide Therapeutics Market Route of Administration Estimates & Trend Analysis
7.1 Peptide Therapeutics market: Route of Administration movement analysis
7.2 Parenteral
7.2.1 Parenteral market, 2017 - 2030 (USD Million)
7.3 Oral
7.3.1 Oral market, 2017 - 2030 (USD Million)
7.4 Pulmonary
7.4.1 Pulmonary market, 2017 - 2030 (USD Million)
7.5 Mucosal
7.5.1 Mucosal market, 2017 - 2030 (USD Million)
7.6 Others
7.6.1 Others market, 2017 - 2030 (USD Million)

Chapter 8 Peptide Therapeutics Market Synthesis Technology Estimates & Trend Analysis
8.1 Peptide Therapeutics market: Synthesis Technology movement analysis
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
8.4 Hybrid Technology
8.4.1 Hybrid Technology market, 2017 - 2030 (USD Million)

Chapter 9 Peptide Therapeutics Market: Regional Estimates & Trend Analysis, by Source, Product, Application
9.1 Peptide Therapeutics market share by region, 2021 & 2030
9.2 North America
9.2.1 North America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.3 Canada
9.2.3.1 Canada Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3 Europe
9.3.1 Europe Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.2 U.K.
9.3.2.1 U.K. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.3 Germany
9.3.3.1 Germany Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Japan Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.3 China
9.4.3.1 China Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.4 India
9.4.4.1 India Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5 Latin America
9.5.1 Latin America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.3 Mexico
9.5.3.1 Mexico Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6 MEA
9.6.1 MEA Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa Peptide Therapeutics market, 2017 - 2030 (USD Million)

Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Market Participation
10.3 Company Profiles
10.3.1 Bachem Holding AG
10.3.1.1 Company overview
10.3.1.2 Financial performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategic initiatives
10.3.2 Eli Lilly and Company
10.3.2.1 Company overview
10.3.2.2 Financial performance
10.3.2.3 Product benchmarking
10.3.2.4 Strategic initiatives
10.3.3 Pfizer Inc.
10.3.3.1 Company overview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategic initiatives
10.3.4 Amgen Inc.
10.3.4.1 Company overview
10.3.4.2 Financial performance
10.3.4.3 Product benchmarking
10.3.4.4 Strategic initiatives
10.3.5 Takeda Pharmaceutical Company Limited
10.3.5.1 Company overview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategic initiatives
10.3.6 Teva Pharmaceutical
10.3.6.1 Company overview
10.3.6.2 Financial performance
10.3.6.3 Product benchmarking
10.3.6.4 Strategic initiatives
10.3.7 Lonza Inc.
10.3.7.1 Company overview
10.3.7.2 Financial performance
10.3.7.3 Product benchmarking
10.3.7.4 Strategic initiatives
10.3.8 Sanofi
10.3.8.1 Company overview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategic initiatives
10.3.9 Bristol-Myers Squibb(BMS)
10.3.9.1 Company overview
10.3.9.2 Financial performance
10.3.9.3 Product benchmarking
10.3.9.4 Strategic initiatives
10.3.10 AstraZeneca PLC
10.3.10.1 Company overview
10.3.10.2 Financial performance
10.3.10.3 Product benchmarking
10.3.10.4 Strategic initiatives
10.3.11 GlaxoSmithKline (GSK)
10.3.11.1 Company overview
10.3.11.2 Financial performance
10.3.11.3 Product benchmarking
10.3.11.4 Strategic initiatives
10.3.12 Novartis AG
10.3.12.1 Company overview
10.3.12.2 Financial performance
10.3.12.3 Product benchmarking
10.3.12.4 Strategic initiatives
10.3.13 Novo Nordisk A/S
10.3.13.1 Company overview
10.3.13.2 Financial performance
10.3.13.3 Product benchmarking
10.3.13.4 Strategic initiatives

List of Tables
TABLE 1 Factors used in segment share estimation
TABLE 2 List of secondary data sources
TABLE 3 Primary interview details, by source
TABLE 4 Primary interview details, by region
TABLE 5 North America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 6 North America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 7 North America Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 8 North America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 9 North America Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 10 U.S. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 11 U.S. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 12 U.S. Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 13 U.S. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 14 U.S. Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 15 Canada Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 16 Canada Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 17 Canada Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 18 Canada Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 19 Canada Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 20 Europe Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 21 Europe Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 22 Europe Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 23 Europe Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 24 Europe Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 25 U.K. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 26 U.K. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 27 U.K. Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 28 U.K. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 29 U.K. Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 30 Germany Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 31 Germany Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 32 Germany Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 33 Germany Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 34 Germany Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 35 Asia Pacific Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 36 Asia Pacific Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 37 Asia Pacific Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 38 Asia Pacific Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 39 Asia Pacific Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 40 Japan Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 41 Japan Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 42 Japan Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 43 Japan Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 44 Japan Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 45 China Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 46 China Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 47 China Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 48 China Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 49 China Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 50 India Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 51 India Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 52 India Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 53 India Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 54 India Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 55 Latin America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 56 Latin America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 57 Latin America Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 58 Latin America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 59 Latin America Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 60 Brazil America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 61 Brazil Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 62 Brazil Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 63 Brazil Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 64 Brazil Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 65 Mexico America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 66 Mexico Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 67 Mexico Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 68 Mexico Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 69 Mexico Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 70 MEA America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 71 MEA Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 72 MEA Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 73 MEA Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 74 MEA Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 75 South Africa Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 76 South Africa Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 77 South Africa Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 78 South Africa Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 79 South Africa Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)

List of Figures
FIG. 1 Primary interviews, by sources
FIG. 2 Market summary
FIG. 3 Market trends & outlook
FIG. 4 Market segmentation & scope
FIG. 5 Market driver relevance analysis (Current & future impact)
FIG. 6 Market restraint relevance analysis (Current & future impact)
FIG. 7 Key opportunities prioritized
FIG. 8 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 9 Porter’s Five Forces Analysis
FIG. 10 Peptide Therapeutics market, Application outlook: Key takeaways
FIG. 11 Peptide Therapeutics market: Application movement analysis
FIG. 12 Cancer market, 2017 - 2030 (USD Million)
FIG. 13 Metabolic market, 2017 - 2030 (USD Million)
FIG. 14 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
FIG. 15 Respiratory market, 2017 - 2030 (USD Million)
FIG. 16 GIT market, 2017 - 2030 (USD Million)
FIG. 17 Anti-infection market, 2017 - 2030 (USD Million)
FIG. 18 Pain market, 2017 - 2030 (USD Million)
FIG. 19 Dermatology market, 2017 - 2030 (USD Million)
FIG. 20 CNS market, 2017 - 2030 (USD Million)
FIG. 21 Renal market, 2017 - 2030 (USD Million)
FIG. 22 Others market, 2017 - 2030 (USD Million)
FIG. 23 Peptide Therapeutics market, type outlook: Key takeaways
FIG. 24 Peptide Therapeutics Market: Type movement analysis
FIG. 25 Generic market, 2017 - 2030 (USD Million)
FIG. 26 Innovative market, 2017 - 2030 (USD Million)
FIG. 27 Peptide Therapeutics market, Type of Manufacturers outlook: Key takeaways
FIG. 28 Peptide Therapeutics Market: Type of Manufacturers movement analysis
FIG. 29 In-house market, 2017 - 2030 (USD Million)
FIG. 30 Outsourced market, 2017 - 2030 (USD Million)
FIG. 31 Peptide Therapeutics market, Route of Administration outlook: Key takeaways
FIG. 32 Peptide Therapeutics Market: Route of Administration movement analysis
FIG. 33 Parental market, 2017 - 2030 (USD Million)
FIG. 34 Oral market, 2017 - 2030 (USD Million)
FIG. 35 Pulmonary market, 2017 - 2030 (USD Million)
FIG. 36 Mucosal market, 2017 - 2030 (USD Million)
FIG. 37 Others market, 2017 - 2030 (USD Million)
FIG. 38 Peptide Therapeutics market, Synthesis Technology outlook: Key takeaways
FIG. 39 Peptide Therapeutics Market: Synthesis Technology movement analysis
FIG. 40 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
FIG. 41 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
FIG. 42 Hybrid Technology market, 2017 - 2030 (USD Million)
FIG. 43 Regional market place: Key takeaways
FIG. 44 Regional outlook, 2021 & 2030
FIG. 45 Strategy framework
FIG. 46 Market participation and categorization